Aims: We investigated the prevalence of the myocyte enhancer factor (MEF)2A exon 11 deletion, a putative coronary artery disease (CAD) susceptibility gene, in patients referred for coronary angiography.
Methods and results: In total, 1079 consecutive patients referred for coronary angiography in the GENICA Study were genotyped and 301 low-risk subjects were used as controls. One patient with early onset three vessels CAD, carrying the MEF2A deletion was found in the GENICA Study cohort and none in the control group.
Conclusion: In a cohort of patients undergoing coronary angiography for suspected CAD the MEF2A exon 11 deletion occurred in 0.09%.
AssmannGCullenPSchulteH. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation2002; 105: 310–310.
2.
RaikoJRMagnussenCGKivimakiMTaittonenLLaitinenTKahonenM. Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young Finns study. Eur J Cardiovasc Prev Rehabil2010; 17: 549–549.
3.
CesariMMaiolinoGColonnaSZanchettaMPedonLMaiolinoP. Under treatment with lipid-lowering drugs of high-risk coronary heart disease patients of the GENICA study. J Cardiovasc Pharmacol2003; 42: 484–484.
4.
ShiffmanDChasmanDIZeeRYIakoubovaOALouieJZDevlinJJ. A kinesin family member 6 variant is associated with coronary heart disease in the Women's Health Study. J Am Coll Cardiol2008; 51: 444–444.
5.
WangLFanCTopolSETopolEJWangQ. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science2003; 302: 1578–1578.
6.
BlackBLMolkentinJDOlsonEN. Multiple roles for the MyoD basic region in transmission of transcriptional activation signals and interaction with MEF2. Mol Cell Biol1998; 18: 69–69.
7.
EdmondsonDGLyonsGEMartinJFOlsonEN. Mef2 gene expression marks the cardiac and skeletal muscle lineages during mouse embryogenesis. Development1994; 120: 1251–1251.
8.
KajimotoKShiojiKTagoNTomoikeHNonogiHGotoY. Assessment of MEF2A mutations in myocardial infarction in Japanese patients. Circ J2005; 69: 1192–1192.
9.
LiebWMayerBKonigIRBorwitzkyIGotzAKainS. Lack of association between the MEF2A gene and myocardial infarction. Circulation2008; 117: 185–185.
10.
GuellaIRimoldiVAsseltaRArdissinoDFrancoliniMMartinelliN. Association and functional analyses of MEF2A as a susceptibility gene for premature myocardial infarction and coronary artery disease. Circ Cardiovasc Genet2009; 2: 165–165.
11.
WengLKavaslarNUstaszewskaADoelleHSchackwitzWHebertS. Lack of MEF2A mutations in coronary artery disease. J Clin Invest2005; 115: 1016–1016.
12.
ManciaGDe BackerGDominiczakACifkovaRFagardRGermanoG. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens2007; 25: 1751–1751.
13.
RossiGPCesariMDe ToniRZanchettaMMaiolinoGPedonL. Antibodies to oxidized low-density lipoproteins and angiographically assessed coronary artery disease in white patients. Circulation2003; 108: 2467–2467.
14.
RossiGPCesariMZanchettaMColonnaSMaiolinoGPedonL. The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol2003; 41: 930–930.
15.
RossiGPMaiolinoGZanchettaMSticchiDPedonLCesariM. The T(-786)C endothelial nitric oxide synthase genotype predicts cardiovascular mortality in high-risk patients. J Am Coll Cardiol2006; 48: 1166–1166.
16.
HoranPGAllenARHughesAEPattersonCCSpenceMMcGlincheyPG. Lack of MEF2A Delta7aa mutation in Irish families with early onset ischaemic heart disease, a family based study. BMC Med Genet2006; 7: 65–65.
